Navigation Links
Novel gene predicts local recurrence in early-onset breast cancer
Date:5/5/2009

HOUSTON - A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine.

"The correlation with local recurrence is significant because so many young women have recurrences in the breast, and cancers that do recur tend to be more aggressive," said senior author Ann McNeill Killary, Ph.D., professor in M. D. Anderson's Department of Genetics. "Young age has been considered a risk factor for local recurrence and metastasis. It is important to understand the genetic mechanisms operating in early-onset breast cancer and to determine whether there is a way to identify young women who might be at a higher risk of recurrence."

After Killary's laboratory research discovered DEAR1 (ductal epithelium-associated ring chromosome 1) and implicated it in breast cancer, the team examined a tumor tissue microarray from 123 women whose breast cancer began between ages 25 and 49, all of whom advanced to invasive disease. Of these, 56 percent lacked DEAR1 expression in their tumors, which was associated with 58 percent local recurrence-free survival 15 years after surgery. For those with DEAR1 expression, local recurrence-free survival was 95 percent at 15 years.

"Immunohistochemical staining for DEAR1 could potentially be performed in any hospital setting, and such an assay might predict which women are at a high risk of recurrence and potentially help guide treatment decisions" Killary said, noting the results will need to be validated in a larger cohort of patients.

Breast cancer that develops before age 50 tends to be more aggressive and more likely to recur even in the absence of invasion of the lymph nodes at diagnosis. "Approximately one-fourth of women without nodal involvement will experience a
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
2. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
3. Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
4. Spiritual Leaders Teachings Collected in New Novel
5. Novel role of protein in generating amyloid-beta peptide
6. Novel cancer drug reduces neuroblastoma growth by 75 percent
7. Porter Novelli Begins Work With NHLBI on COPD Awareness Effort
8. Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages
9. Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries
10. Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimers disease
11. A Decision Beyond Life and Death: Novel Examines Effects of Controversial Procedure on Patients, Their Families and Doctors

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel gene predicts local recurrence in early-onset breast cancer
Novel gene predicts local recurrence in early-onset breast cancer
(Date:12/2/2009)... , SAN DIEGO, Dec. 2 ... supplier of Farming, Nursery and Wellness product...s Aloe365(TM) products at the Cook,sware A,faire i...11-20, 2009. ,, For additional information, con... 877-90-FARMS or visit http://cookswareafaire.com...
(Date:12/2/2009)..., WASHINGTON and REDMOND, Wash., Dec. 2 /PRNe...ounced the companies will collaborate to give care...re information necessary for providing ongoing car...tients and their families better tools for managin...st post-acute care organization to adopt Microsoft...
(Date:12/2/2009)...king it for macular degeneration is not advised, ...hDay News) -- Women who take low-dose aspirin to p...well. , A new study by Harvard University resea...it for aspirin in preventing age-related macular d...arp, central vision. , "The data indicate that ...
(Date:12/2/2009)..., CHICAGO, Dec. 2 ,...uidelines Controversy ,, A special press brief...CT (11:45 a.m. ET), featuring a panel of top exper...vices Task Force (USPSTF) release of revised scree... cancer survivors, medical experts and government ...
(Date:12/2/2009)... 3D animation detailing plastic su...Elements website. Surgical candidates can view pro...tly from the page. , (PRW...ne compression garments retailer, has always been ...ry patients after their procedures, providing lipo...
Breaking Medicine News(10 mins):Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 2Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 4Health News:In Women, Aspirin Might Ward Off Eye Trouble 2Health News:Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Health News:Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Health News:Online Compression Garments Retailer Introduces 3D Animation of Surgical Procedures 2
...re-FirstCall/ -- Xi,an 38 Fule,Health & Advisory, ...oday,announced that the Company has begun trading ... symbol XNFHF. OTCQX provides a premier trading,qu...closure., "As a member of OTCQX, we look forward ...
...ronic, Inc., one of,the world,s leading developers...ced today that its MOSAIC eCO2 system, the next ge...g fractional technology with the deep,ablative fea...ontoured scanner hand piece with adjustable contro...
...ormance Program Continues to Take Root ...ay 30 Independence Blue Cross (IBC) and,Holy Rede...ced that they,have reached agreement on new contra... three years to January 1, 2011., "We,ve enjoyed ...
...TORONTO, May 30 /PRNewswire-FirstCall/ - Predictiv...) today announced it has been notified by,the Amer...continue to,support PreMD,s plan for regaining com...ion with the Securities and Exchange,Commission (t...
...y, Presentations at http://www.sto-online.org , ...ology,(STO) is pleased to announce the launch of i...uable video presentations for practicing,oncologis... American Society of Clinical Oncology (ASCO), bei...
...e less likely than white women to receive the radi...ry for early breast cancer, according to a study t...present at the annual meeting of the American Soci... breast cancer patients may be undertreated follow...
Other Medicine News:Health News:Xi'an 38 Fule Health & Advisory, LTD Lists on International OTCQX 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:IBC Signs New Agreements with Holy Redeemer Health System 2Health News:IBC Signs New Agreements with Holy Redeemer Health System 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Society for Translational Oncology Launches Updated Website 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2
(Date:12/2/2009)..., NEW YORK, Dec. 2 Kery...announced that the U.S. Food and Drug Administrati...X-0401 (perifosine), the Company,s novel, potentia...hibits the phosphoinositide 3-kinase (PI3K)/Akt pa...ltiple myeloma. ,, The Fast Track program of ...
(Date:12/2/2009)...BIRMINGHAM, Ala., Dec. 2 Adults ...osed with cancer. For adults 65 and over, the odds...ds of a man developing prostate cancer are one in ...re one in nine. Vision loss threatens the overall...injuries, depression and inability to complete dai...
(Date:12/2/2009)..., ALISO VIEJO, Calif., Dec. 2 /PRNewswire-FirstCal...echnology and services resource for pathologists, ... announced a Chief Financial Officer transition pl...ael R. Rodriguez to become its Senior Vice Preside.... Raymond J. Land, age 64, the current Senior Vice...
Breaking Medicine Technology:Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2Clarient Announces CFO Transition Plan 2Clarient Announces CFO Transition Plan 3Clarient Announces CFO Transition Plan 4Researchers at Boston University School of Medicine incorporate multisite geriatric clerkship 58687 1Researchers at Boston University School of Medicine incorporate multisite geriatric clerkship 58687 2Natural killer cells keep immune system in balance 10226 1Natural killer cells keep immune system in balance 10226 2Genetic conflict in fish led to evolution of new sex chromosomes 10224 1Genetic conflict in fish led to evolution of new sex chromosomes 10224 2
...Time, Newsweek,and U.S. World and News are all buz...earchers have found compelling evidence that these...ve and immune health, but Eastern,Europeans have b...und in,fermented foods such as yogurt, for centuri...obiotic benefits, Russian scientists have been awa...
...diac Toxicity With Equivalent Co... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: ...ts phase II/III randomized study comparing CPOP-R ...with aggressive non-Hodgkin,s lymphoma,(NHL) showe...s severe,(grade 3/4) toxicities including severe i...
Other Medicine Technology:Are Muramyl Peptides the Magic Bullet in Probiotics? 2Are Muramyl Peptides the Magic Bullet in Probiotics? 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
VascoTip E 9/60 PU S
VascoTip CC 9/60 M
VascoTip E 9/60 S
VascoTwist E 9/60 M
Medicine Products: